| Five-year follow-up of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. | |
| | |
MedLine Citation:
|
PMID: 17339566 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Despite routine use of coronary artery bypass graft (CABG) and percutaneous coronary intervention (PCI), no conclusive evidence exists that either modality is superior to medical therapy (MT) alone for treating multivessel coronary artery disease with stable angina and preserved ventricular function. METHODS AND RESULTS: The primary end points were total mortality, Q-wave myocardial infarction, or refractory angina requiring revascularization. The study comprised 611 patients randomly assigned to undergo CABG (n=203), PCI (n=205), or MT (n=203). At the 5-year follow-up, the primary end points occurred in 21.2% of patients who underwent CABG compared with 32.7% treated with PCI and 36% receiving MT alone (P=0.0026). No statistical differences were observed in overall mortality among the 3 groups. In addition, 9.4% of MT and 11.2% of PCI patients underwent repeat revascularization procedures compared with 3.9% of CABG patients (P=0.021). Moreover, 15.3%, 11.2%, and 8.3% of patients experienced nonfatal myocardial infarction in the MT, PCI, and CABG groups, respectively (P<0.001). The pairwise treatment comparisons of the primary end points showed no difference between PCI and MT (relative risk, 0.93; 95% confidence interval, 0.67 to 1.30) and a significant protective effect of CABG compared with MT (relative risk, 0.53; 95% confidence interval, 0.36 to 0.77). CONCLUSIONS: All 3 treatment regimens yielded comparable, relatively low rates of death. MT was associated with an incidence of long-term events and rate of additional revascularization similar to those for PCI. CABG was superior to MT in terms of the primary end points, reaching a significant 44% reduction in primary end points at the 5-year follow-up of patients with stable multivessel coronary artery disease. |
| | |
Authors:
|
Whady Hueb; Neuza Helena Lopes; Bernard J Gersh; Paulo Soares; Luiz A C Machado; Fabio B Jatene; Sergio A Oliveira; Jose A F Ramires |
Related Documents
:
|
19343126 - The diagnosis and treatment of the no-reflow phenomenon in patients with myocardial inf... 18848686 - Factors predictive for in-hospital mortality following percutaneous coronary intervention. 10577466 - Should the emergence of new agents change the management of patients with acute coronar... 20853136 - Clinical impact of simultaneous complete revascularization vs. culprit only primary ang... 9293826 - The utility of dobutamine echocardiography in preoperative evaluation for elective aort... 1117746 - Transvenous atrial pacing with a new electrode. |
Publication Detail:
|
Type: Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Circulation Volume: 115 ISSN: 1524-4539 ISO Abbreviation: Circulation Publication Date: 2007 Mar |
Date Detail:
|
Created Date: 2007-03-06 Completed Date: 2007-03-27 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0147763 Medline TA: Circulation Country: United States |
Other Details:
|
Languages: eng Pagination: 1082-9 Citation Subset: AIM; IM |
Affiliation:
|
Heart Institute of the University of São Paulo, São Paulo, Brazil. whady.hueb@incor.usp.br |
| Data Bank Information | |
Bank Name/Acc. No.:
|
ISRCTN/ISRCTN66068876 |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adrenergic beta-Antagonists
/
therapeutic use Aged Angina Pectoris / drug therapy, surgery, therapy Angioplasty, Transluminal, Percutaneous Coronary* / statistics & numerical data Angiotensin-Converting Enzyme Inhibitors / therapeutic use Calcium Channel Blockers / therapeutic use Cardiovascular Agents / therapeutic use* Coronary Artery Bypass* / statistics & numerical data Coronary Disease / diet therapy, drug therapy, mortality, surgery, therapy* Coronary Restenosis / epidemiology, surgery, therapy Diet, Fat-Restricted Disease-Free Survival Drug Therapy, Combination Electrocardiography Endpoint Determination Female Follow-Up Studies Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use Male Middle Aged Myocardial Infarction / epidemiology, etiology, prevention & control Nitrates / therapeutic use Prognosis Reoperation Stents Survival Analysis Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Adrenergic beta-Antagonists; 0/Angiotensin-Converting Enzyme Inhibitors; 0/Calcium Channel Blockers; 0/Cardiovascular Agents; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Nitrates |
| Comments/Corrections | |
Comment In:
|
Circulation. 2007 Mar 6;115(9):1064-6
[PMID:
17339563
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Nonfatal acute myocardial infarction in Costa Rica: modifiable risk factors, population-attributable...
Next Document: Predictors of mortality in chronic Chagas disease: a systematic review of observational studies.